Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

Yasuo Terauchi; Yoichi Satoi; Masakazu Takeuchi; Takeshi Imaoka

doi:10.1507/endocrj.ej14-0147

Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study

Endocrine Journal ◽

10.1507/endocrj.ej14-0147 ◽

2014 ◽

Vol 61 (10) ◽

pp. 949-959 ◽

Cited By ~ 28

Author(s):

Yasuo Terauchi ◽

Yoichi Satoi ◽

Masakazu Takeuchi ◽

Takeshi Imaoka

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Dependent

Download Full-text

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study

Diabetic Medicine ◽

10.1111/j.1464-5491.2012.03745.x ◽

2012 ◽

Vol 29 (10) ◽

pp. 1260-1267 ◽

Cited By ~ 61

Author(s):

G. Grunberger ◽

A. Chang ◽

G. Garcia Soria ◽

F. T. Botros ◽

R. Bsharat ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Dependent

Download Full-text

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

Journal of Diabetes Investigation ◽

10.1111/jdi.12749 ◽

2017 ◽

Vol 9 (3) ◽

pp. 558-566 ◽

Cited By ~ 1

Author(s):

Antonio Nino ◽

Inaha Okuda ◽

Timothy H Wilson ◽

Lynn Yue ◽

Hiromu Nakajima ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2012.01590.x ◽

2012 ◽

Vol 14 (6) ◽

pp. 565-574 ◽

Cited By ~ 96

Author(s):

T. Haak ◽

T. Meinicke ◽

R. Jones ◽

S. Weber ◽

M. von Eynatten ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Initial Combination

Download Full-text

Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/review1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Decision letter for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes Obesity and Metabolism ◽

10.1111/dom.13979 ◽

2020 ◽

Vol 22 (6) ◽

pp. 938-946 ◽

Cited By ~ 5

Author(s):

Juan Pablo Frias ◽

Michael A. Nauck ◽

Joanna Van ◽

Charles Benson ◽

Ross Bray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Insulinotropic Peptide

Download Full-text

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12047 ◽

2013 ◽

Vol 15 (5) ◽

pp. 432-440 ◽

Cited By ~ 90

Author(s):

K. Kaku ◽

S. Inoue ◽

O. Matsuoka ◽

A. Kiyosue ◽

H. Azuma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycaemic Control ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Diabetic Medicine ◽

10.1111/j.1464-5491.2010.03020.x ◽

2010 ◽

Vol 27 (9) ◽

pp. 1024-1032 ◽

Cited By ~ 108

Author(s):

R. E. Ratner ◽

J. Rosenstock ◽

G. Boka ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Dose Dependent

Download Full-text

Review for "Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP‐1 Receptor Agonist in Patients with Type 2 Diabetes: A 12‐Week, Randomised, Double‐Blind, Placebo‐Controlled Study to Evaluate Different Dose‐Escalation Regimens"

10.1111/dom.13979/v1/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Dose Escalation ◽

Receptor Agonist ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12331 ◽

2014 ◽

Vol 17 (3) ◽

pp. 304-308 ◽

Cited By ~ 63

Author(s):

A. Kashiwagi ◽

K. Kazuta ◽

K. Goto ◽

S. Yoshida ◽

E. Ueyama ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text